Compare WSR & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSR | MNKD |
|---|---|---|
| Founded | 1998 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 973.9M | 877.0M |
| IPO Year | 2002 | 2004 |
| Metric | WSR | MNKD |
|---|---|---|
| Price | $18.98 | $3.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $19.00 | $8.69 |
| AVG Volume (30 Days) | 372.0K | ★ 6.0M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.01% | N/A |
| EPS Growth | ★ 31.94 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | $160,859,000.00 | ★ $348,966,000.00 |
| Revenue This Year | $2.77 | $35.81 |
| Revenue Next Year | $4.21 | $11.89 |
| P/E Ratio | $237.19 | ★ N/A |
| Revenue Growth | 4.26 | ★ 22.23 |
| 52 Week Low | $11.43 | $2.23 |
| 52 Week High | $19.01 | $6.51 |
| Indicator | WSR | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 79.79 | 57.51 |
| Support Level | $18.90 | $2.56 |
| Resistance Level | $19.00 | $6.08 |
| Average True Range (ATR) | 0.03 | 0.25 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 41.67 | 31.46 |
Whitestone REIT is a real estate investment trust (REIT) that owns and operates commercial properties in culturally diverse metropolitan markets. The company's primary business objective is to increase shareholder value by acquiring, owning, and operating Community Centered Properties. Its property portfolio includes retail and mixed-use properties located in business-friendly locations in and around Austin, Scottsdale, Dallas, Houston, Phoenix, Arizona, and San Antonio. The properties are convenience-focused: merchandised with a mix of service-oriented tenants providing food (restaurants and grocers), self-care (health and fitness), services (financial and logistics), education, and entertainment to the surrounding communities.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.